WATCH THE 
webinar


Catching the Next Wave of Platforms & Companies

We realize the word paradigm is overused, especially in BioPharma. And doubly so in Oncology. The pace of our increased understanding of biology, cancer, the immune system, and the evolution of how to engineer in and/or around them are both so rapid that paradigms are overturned almost on a weekly basis. 

And yet some common themes are emerging in both the target landscape and therapeutic modalities. For one, problematic targets, intractable or undruggable, are in fact being addressed via novel small molecule approaches like target protein degradation. Or new ways, on top of RNAi and gene editing, are modulating protein function via targeting of transcription or translation. Biologics, a mainstay of therapy in many cancers, is evolving towards greater efficacy and safety as well as a greater diversity of activity, including multi-functionalities, such as bispecifics and local activation. Adoptive cell therapies (ACT) are taking many technologies to create living drugs, and are moving towards off-the-shelf formats. And finally, a nascent area that is looking to move the multifunctionality and power of ACT inside the patient’s own body, so-called endogenous reprogramming.

This webinar part of a continuing series of forward-looking sessions as Linda Pullan and Jeff Bockman lead a virtual panel of Oncology luminaries with diverse perspectives including VC, Pharma, Biotech, and Strategic Consulting, in discussing the scientific, clinical, business development, and commercial opportunities and challenges in bringing these novel approaches into the clinic and ultimately to patients.

Come hear as our panelists answer some big questions:

  • What does it take to attract investors to a new approach?
  • What attracts partners to a new platform?
  • What data do they need to see?
  • What are the challenges of development for multifunctionals and pleotropic targets compared to single target drug candidates?
  • How do you think about patient stratification with these novel approaches, whether multi-functional or not?

 

EXPERT PANEL

Company team

Mary Haak-Frendscho, PhD

CEO, Spotlight Therapeutics

Dr. Haak-Frendscho serves as President and CEO of Spotlight Therapeutics. She has over two decades of expertise in the discovery, translation and early development of novel therapeutics primarily for the treatment of immunological and oncological diseases. Prior to Spotlight, she was a venture partner with Versant Ventures and CEO of Blueline Bioscience, Versant’s vehicle for new company creation in Canada. Earlier Dr. Haak-Frendscho established and served as Chairman of Compugen, Inc., CEO of Igenica Biotherapeutics, and was the founding President and CSO of Takeda San Francisco. Mary began her industry career at Genentech, where she played a key role in the development of omalizumab (Xolair®).

Dr. Haak-Frendscho has 70 scientific publications and over 40 patents. An immunologist by training, she received her BS from the University of Michigan, MLA from Washington University, MS from SUNY-Stony Brook, CSEP from Columbia University Graduate School of Business, and PhD from the University of Wisconsin. Learn More

Company team

Linda Pullan, PhD

Moderator | Founder, Pullan Consulting

Linda and her team at Pullan Consulting offer biotech and pharmaceutical companies consulting in all aspects of partnering. Linda has a PhD in Biochemistry, a BS in Chemistry, and over twenty years of drug industry experience, including work on more than 75 deals. Learn More

Company team

Jeffrey M. Bockman, PhD

EVP, Oncology Practice Head, Cello Health BioConsulting

Jeff leads the Oncology and Virology Practices at Cello Health BioConsulting (Previously Defined Health). He received a BA from the University of California at San Diego, a PhD in Medical Microbiology from the University of California at Berkeley, and an MA in English/Creative Writing from New York University. Learn More
Company team

Katherine Bowdish, PhD

President & CEO, PIC Therapeutics

Dr. Bowdish joined PIC Therapeutics as its President & CEO in August 2020, bringing more than 20 years of biopharmaceutical business and scientific leadership to the company. 

Kathy was most recently at Sanofi, where she launched and led Sanofi Sunrise, a venture investment and partnering vehicle to accelerate early-stage pioneering science for patients benefit, and more recently served as Vice President and Head of R&D Strategy.

Prior to her leadership roles at Sanofi, Kathy co-founded or led several early-stage life science companies focused on biological therapies. Kathy’s positions include President & CSO, Permeon Biologics; President & CEO, Anaphore; President, Alexion Antibody Technologies and Senior Vice President, Alexion Pharmaceuticals and Founder, CEO & CSO, Prolifaron, prior to its acquisition by Alexion. 

Kathy has served on the Boards of Directors of MyoKardia, Warp Drive Bio, Portal Instruments, Thermalin, Permeon Biologics, Anaphore and Prolifaron, and most recently as an Observer on the DiCE Molecules Board. Kathy received her Ph.D. in molecular genetics from Columbia University College of Physicians and Surgeons, and her B.Sc. degree in biology from the College of William and Mary. Learn More

Company team

Paul Juniewicz, PhD

Distinguished Fellow, Oncology, Takeda

Paul Juniewicz is a Senior Director responsible for oncology search and evaluation within the Takeda Oncology Business Development group. Paul received his BS from Rutgers University, MS and PhD from North Carolina State University and conducted post-doctoral training at Johns Hopkins University. Learn More
Company team

Andrew Pierce, PhD

Vice President, Translational Biology, Crescendo Biologics

Andrew Pierce has spent eighteen years directing and mentoring teams of PhDs and associates translating science into clinical oncology drug development: 10 in industry and 8 in academia. Aligning targeted drugs and combinations to optimal clinical settings and individual patients. Andrew has International leadership for both large and small molecules. Learn More
Company team

Carolyn Ng, PhD

Managing Director, Vertex Ventures

Carolyn Ng is Managing Director at Vertex Ventures HC. At Vertex HC, Carolyn leads venture investments across biotechnology, medical devices, and health technology fields. Carolyn currently serves on the Board of Directors for Epirium Bio, Obsidian Therapeutics, Twentyeight-Seven Therapeutics, Boundless Bio, and Nuvaira. She led Vertex HC’s investment into Elevate Bio, was previously on the Board of Directors of Bicycle Therapeutics (NASDAQ: BCYC), and a Board Observer for Visterra before it was acquired by Otsuka Pharmaceutical for USD430M. She has previously closely supported Vertex’s investment into Twelve (acquired by Medtronic for USD458M). Working across the US, Europe and Asia, she plays an active role in expanding the geographical reach of Vertex HC and its portfolio companies for cross-border collaborations, business development and syndication.

She started her healthcare training in the oncology pharmacy department of the National University Cancer Institute of Singapore, where first-hand clinical experience inspired her to pursue scientific research in oncology. As an oncology scientist, she is deeply passionate about innovation that impacts patients’ lives. Prior to joining Vertex, Carolyn was also a Pharma Strategy Consultant at Deallus Consulting, a specialized London-headquartered life sciences consulting firm where she led global strategic projects for clientele comprised of the top 20 global pharmaceutical companies.

Carolyn holds a PhD in Cancer Molecular Biology from the NUS Graduate School for Integrative Sciences and Technology (NGS), where she was a recipient of the prestigious NGS PhD Scholarship. As an inventor and patent holder of a novel small molecule nuclear receptor activator indicated for the treatment of neuroblastoma, her research work was awarded the AAPS-NUS Prize (American Association of Pharmaceutical Society-National University of Singapore). She also holds a BS degree in Pharmacy with First Class Honours from the National University of Singapore, where she received the PSS Prize for Pharmaceutics awarded to the top graduating student in the class.

Outside of Vertex, Carolyn is a retired competitive squash player, a high-intensity interval training enthusiast, and an aspiring but untalented oil painter. Learn More

     IN COLLABORATION WITH:

Demo Logo